<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" nameag="viewport"/>
<title>Pharmacology - INICET MAY 2024</title>
<script src="https://cdn.tailwindcss.com"></script>
<script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
<script src="https://cdn.jsdelivr.net/npm/canvas-confetti@1.6.0/dist/confetti.browser.min.js"></script>
<style>
        /* Custom styles for enhanced aesthetics and responsiveness */
        .option-btn {
            transition: all 0.3s ease;
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
        }
        .option-btn:hover, .option-btn:active {
            transform: scale(1.02);
            box-shadow: 0 4px 8px rgba(0, 0, 0, 0.2);
        }
        .option-btn.selected {
            background-color: #3b82f6;
            color: white;
        }
        .marked {
            background-color: #fef08a;
        }
        .progress-bar {
            transition: width 0.5s ease-in-out;
            background: linear-gradient(to right, #3b82f6, #22c55e);
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.2);
            animation: pulse 2s infinite;
        }
        @keyframes pulse {
            0% { opacity: 1; }
            50% { opacity: 0.8; }
            100% { opacity: 1; }
        }
        .question-nav-btn, .result-nav-btn-grid {
            width: 40px;
            height: 40px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 8px;
            font-size: 16px;
            touch-action: manipulation;
            transition: all 0.2s ease;
        }
        .question-nav-btn:hover, .question-nav-btn:active, .result-nav-btn-grid:hover, .result-nav-btn-grid:active {
            transform: scale(1.05);
        }
        .answered {
            background-color: #22c55e;
            color: white;
        }
        .unanswered {
            background-color: #e5e7eb;
        }
        .marked-nav {
            border: 2px solid #fef08a;
        }
        .video-container, .audio-container {
            display: none;
            position: relative;
        }
        .video-container.active, .audio-container.active {
            display: block;
            animation: fadeIn 0.5s ease-in;
        }
        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }
        .section-transition {
            transition: opacity 0.3s ease;
        }
        .section-transition.hidden {
            opacity: 0;
            pointer-events: none;
        }
        .result-nav {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-top: 1rem;
        }
        .result-nav-btn {
            background-color: #4b5563;
            color: white;
            padding: 0.5rem 1rem;
            border-radius: 8px;
            transition: all 0.2s ease;
        }
        .result-nav-btn:hover, .result-nav-btn:active {
            background-color: #374151;
            transform: scale(1.05);
        }
        .result-nav-btn:disabled {
            background-color: #d1d5db;
            cursor: not-allowed;
        }
        .error-message {
            color: #dc2626;
            font-weight: bold;
            margin-top: 1rem;
        }
        /* Mobile-specific adjustments */
        @media (max-width: 640px) {
            .question-nav-btn, .result-nav-btn-grid {
                width: 38px;
                height: 38px;
                font-size: 14px;
            }
            .nav-panel, .results-nav-panel {
                width: 100%;
                max-width: 100%;
                overscroll-behavior: contain;
            }
            .option-btn {
                padding: 12px;
                font-size: 14px;
            }
            .header-text {
                font-size: 1.5rem;
            }
            .subheader-text {
                font-size: 0.875rem;
            }
            .button-group, .result-nav {
                flex-direction: column;
                gap: 0.5rem;
            }
            .result-nav-btn {
                width: 100%;
                text-align: center;
            }
        }
        /* Dark mode styles */
        .dark .bg-gray-100 {
            background-color: #1f2937;
        }
        .dark .bg-white {
            background-color: #374151;
        }
        .dark .text-gray-700 {
            color: #d1d5db;
        }
        .dark .text-gray-800 {
            color: #e5e7eb;
        }
        .dark .bg-gray-200 {
            background-color: #4b5563;
        }
        .dark .border {
            border-color: #4b5563;
        }
        .dark .bg-blue-500 {
            background-color: #2563eb;
        }
        .dark .hover\:bg-blue-600:hover {
            background-color: #1d4ed8;
        }
        .dark .bg-yellow-300 {
            background-color: #b45309;
            color: white;
        }
        .dark .hover\:bg-yellow-400:hover {
            background-color: #92400e;
        }
        .dark .bg-green-500 {
            background-color: #15803d;
        }
        .dark .hover\:bg-green-600:hover {
            background-color: #166534;
        }
        .dark .bg-gray-500 {
            background-color: #4b5563;
        }
        .dark .hover\:bg-gray-600:hover {
            background-color: #374151;
        }
        .dark .result-nav-btn, .dark .result-nav-btn-grid {
            background-color: #2563eb;
        }
        .dark .result-nav-btn:hover, .dark .result-nav-btn:active, .dark .result-nav-btn-grid:hover, .dark .result-nav-btn-grid:active {
            background-color: #1d4ed8;
        }
        .dark .result-nav-btn:disabled, .dark .result-nav-btn-grid:disabled {
            background-color: #4b5563;
        }
        .video-placeholder {
            width: 400px;
            height: 300px;
            background-color: #f0f0f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            margin-top: 10px;
            border-radius: 8px;
            border: 1px solid #ccc;
        }
        .play-icon {
            font-size: 40px;
            color: #007bff;
        }
        .video-loading {
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            border: 4px solid #f3f3f3;
            border-top: 4px solid #3b82f6;
            border-radius: 50%;
            width: 40px;
            height: 40px;
            animation: spin 1s linear infinite;
        }
        @keyframes spin {
            0% { transform: translate(-50%, -50%) rotate(0deg); }
            100% { transform: translate(-50%, -50%) rotate(360deg); }
        }
    </style>

<script>
    // --- GEMINI AUTO-CAPTURE LISTENER ---
    // This function runs immediately after the quiz determines an answer is INCORRECT.
    function captureMistake(questionIndex, questionsData) {
        try {
            const item = questionsData[questionIndex];
            // Use the question text as a unique, stable identifier
            const uniqueId = 'srs_quiz_' + btoa(item.text.substring(0, 50)).replace(/=/g, ''); 

            // 1. Clean and simplify the explanation for storage
            let explanationText = item.explanation || item.correct_answer || "No explanation provided.";
            
            // Strip complex HTML (images, lists) and boilerplate text
            explanationText = explanationText.replace(/<img[^>]*>/g, "[IMAGE]").trim(); // Replace images with placeholder
            explanationText = explanationText.replace(/<p><strong>Ans\. [A-Z]\).*/i, "").trim(); // Remove the repeated Answer line
            explanationText = explanationText.replace(/<p><strong>Educational Objective:<\/strong>.*?<\/p>/gs, "").trim(); // Remove EO block
            explanationText = explanationText.replace(/@dams_new_robot/g, "");
            explanationText = explanationText.replace(/<\/?[^>]+(>|$)/g, " ").trim(); // Final strip of remaining tags

            // 2. Prepare card data
            const cardData = {
                text: item.text,
                answer: item.correct_answer,
                explanation: explanationText.substring(0, 500), // Keep explanations short
                nextReview: 0, // Due immediately
                reviews: 0,
                source: document.title.split('-')[0].trim() || 'Quiz'
            };

            // 3. Save to Local Storage (SRS Bank)
            localStorage.setItem(uniqueId, JSON.stringify(cardData));
            
            console.log(`ðŸ§  Captured Mistake #${questionIndex + 1} from ${document.title}`);

        } catch (e) {
            console.error("SRS Capture Failed:", e);
        }
    }
    // --- END GEMINI AUTO-CAPTURE LISTENER ---
</script>

</head>
<body class="bg-gray-100 font-sans transition-colors duration-300 min-h-screen overflow-y-auto">
<!-- Header Section -->
<header class="bg-blue-600 text-white p-4 shadow-lg">
<div class="container mx-auto">
<h1 class="text-2xl md:text-3xl font-bold header-text">Pharmacology - INICET MAY 2024</h1>
<p class="mt-2 text-sm md:text-base subheader-text">
                13 Questions | 13 Total Marks | 23 min Duration | ~106.15 sec/question
            </p>
<button class="mt-2 bg-gray-200 text-gray-800 px-3 py-1 rounded-lg hover:bg-gray-300 transition dark:bg-gray-600 dark:text-white" id="theme-toggle">
                Toggle Dark Mode
            </button>
</div>
</header>
<!-- Instructions Section -->
<section class="container mx-auto p-4 md:p-6 section-transition" id="instructions">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-xl font-semibold mb-4">Instructions</h2>
<ul class="list-disc list-inside space-y-2 text-gray-700">
<li>This test contains 13 multiple choice questions.</li>
<li>Each question has only one correct answer.</li>
<li>You will have 23 minutes to complete the test.</li>
<li>Click or tap on an option to select your answer.</li>
<li>Use the "Mark for Review" button to revisit questions.</li>
<li>Navigate using Previous/Next buttons or the Questions Navigation panel.</li>
<li>Click "Submit" to finish and view results.</li>
<li>The test will auto-submit when time runs out.</li>
</ul>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="start-test">Start Test</button>


</div>
<div class="error-message hidden" id="error-message"></div>
</div>
</section>
<!-- Quiz Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="quiz">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<!-- Progress Bar -->
<div class="w-full bg-gray-200 rounded-full h-3 mb-4">
<div class="progress-bar h-3 rounded-full" id="progress-bar" style="width: 0%"></div>
</div>
<!-- Question Header -->
<div class="flex flex-col md:flex-row justify-between items-center mb-4">
<h2 class="text-lg font-semibold" id="question-number">Question <span>1</span> of 13</h2>
<p class="text-lg font-semibold mt-2 md:mt-0" id="timer">Time Remaining: <span>00:00</span></p>
</div>
<!-- Question Content -->
<div class="mb-6" id="question-content">
<p class="text-gray-800 mb-4" id="question-text"></p>
<div class="flex flex-wrap gap-4 mb-4" id="question-images"></div>
<div class="space-y-3" id="options"></div>
</div>
<!-- Navigation Buttons -->
<div class="flex flex-col md:flex-row justify-between items-center gap-2 md:gap-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition w-full md:w-auto" disabled="" id="previous-btn">Previous</button>
<button class="bg-yellow-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-yellow-400 transition w-full md:w-auto" id="mark-review">Mark for Review</button>
<button class="bg-blue-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="next-btn">Next</button>
<button class="bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full md:w-auto" id="nav-toggle">Questions Navigation</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="submit-test">Submit Test</button>
</div>
</div>
</section>
<!-- Results Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="results">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-2xl font-semibold mb-4">Pharmacology - INICET MAY 2024 - Results</h2>
<div class="grid grid-cols-1 md:grid-cols-2 gap-4 mb-6">
<p><strong>Correct:</strong> <span id="correct-count">0</span></p>
<p><strong>Wrong:</strong> <span id="wrong-count">0</span></p>
<p><strong>Unanswered:</strong> <span id="unanswered-count">0</span></p>
<p><strong>Marked for Review:</strong> <span id="marked-count">0</span></p>
</div>
<h3 class="text-lg font-semibold mb-4" id="result-question-number">Question <span>1</span> of 13</h3>
<div class="space-y-6" id="results-content"></div>
<div class="result-nav">
<button aria-label="Previous question result" class="result-nav-btn" disabled="" id="prev-result">Previous</button>
<button aria-label="Toggle results navigation panel" class="result-nav-btn" id="results-nav-toggle">Results Navigation</button>
<button aria-label="Next question result" class="result-nav-btn" id="next-result">Next</button>
</div>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="take-again">Take Again</button>
<button class="bg-gray-500 text-white px-6 py-2 rounded-lg hover:bg-gray-600 transition" id="review-test">Review Test</button>
</div>
</div>
</section>
<!-- Exit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="exit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Leave Test?</h2>
<p class="text-gray-700 mb-4">Your progress will be lost if you leave this page. Are you sure you want to exit?</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="continue-test">No, Continue</button>
<button class="bg-red-500 text-white px-4 py-2 rounded-lg hover:bg-red-600 transition" id="exit-test">Yes, Exit</button>
</div>
</div>
</div>
<!-- Submit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="submit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Confirm Submission</h2>
<p class="text-gray-700 mb-2">You have attempted <span id="attempted-count">0</span> of 13 questions.</p>
<p class="text-gray-700 mb-4"><span id="unattempted-count">0</span> questions are unattempted.</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="cancel-submit">Cancel</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-green-600 transition" id="confirm-submit">Submit Test</button>
</div>
</div>
</div>
<!-- Quiz Navigation Panel -->
<div class="fixed inset-y-0 right-0 nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="nav-panel">
<h2 class="text-lg font-semibold mb-4">Questions Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-nav">Close</button>
</div>
<!-- Results Navigation Panel -->
<div class="fixed inset-y-0 right-0 results-nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="results-nav-panel">
<h2 class="text-lg font-semibold mb-4">Results Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="results-nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="results-nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-results-nav">Close</button>
</div>
<!-- JavaScript Logic -->
<script>
        // Enable debug mode for detailed logging
        const DEBUG_MODE = true;

        // Log debug messages
        function debugLog(message) {
            if (DEBUG_MODE) {
                console.log(`[DEBUG] ${message}`);
            }
        }

        // Initialize questions with error handling
        let questions = [];
        let currentResultQuestion = 0; // State for current question in results
        try {
            debugLog("Attempting to parse questions_json");
            questions = [{"text": "Which of the following monoclonal antibodies is a HER - 2 inhibitor?", "options": [{"label": "A", "text": "Pertuzumab", "correct": true}, {"label": "B", "text": "Cetuximab", "correct": false}, {"label": "C", "text": "Panitumumab", "correct": false}, {"label": "D", "text": "Necitumumab", "correct": false}], "correct_answer": "A. Pertuzumab", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Pertuzumab Pertuzumab is a HER2 inhibitor used for breast cancer. Hence option A is correct.</p>\n<p><strong>Highyeild:</strong></p><p>Pertuzumab Pertuzumab is a humanized monoclonal antibody directed against the extracellular receptor dimerization domain II of Pertuzumab prevents ligand-dependent heterodimerization of other HER family members with HER2 and thus inhibits ligand-induced signaling, cell growth, and survival. Use of pertuzumab is approved for the treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer in combination with trastuzumab and docetaxel. Side effect- Cardiotoxicity and combinations with cardiotoxic anthracyclines are not indicated</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: B. Cetuximab is Inhibitors of Epidermal Growth Factor Receptor (EGFR) Function used for colorectal cancer. Option: C. Panitumumab is Inhibitors of Epidermal Growth Factor Receptor (EGFR) Function used for colorectal cancer. Option: D. Necitumumab is Inhibitors of Epidermal Growth Factor Receptor (EGFR) Function used for colorectal cancer.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following drugs acts as an inhibitor of PCSK9?", "options": [{"label": "A", "text": "Bempedoic acid", "correct": false}, {"label": "B", "text": "Ezetimibe", "correct": false}, {"label": "C", "text": "Lomitapide", "correct": false}, {"label": "D", "text": "Evolocumab", "correct": true}], "correct_answer": "D. Evolocumab", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Evolocumab In 2015, two antibodies that target PCSK9 , alirocumab and evolocumab, were approved by the FDA for clinical use in FH and other lipid disorders.</p>\n<p><strong>Highyeild:</strong></p><p>PCSK9 Inhibitors PCSK9 inhibitors prevent degradation of LDL receptors and enhance their recycling to the hepatocyte membrane, thereby facilitating removal of LDL cholesterol and lowering blood LDL cholesterol levels. The PCSK9 inhibitors are administered as subcutaneous injections either every 2 weeks or once monthly. PCSK9 inhibitors should not be used in pregnancy and lactation. The effects of PCSK9 inhibitors are complementary to those of statins . Statins interfere with cholesterol production and stimulate the production of LDL receptors, PCSK9 inhibitors enable more LDL receptors to be available on the surface of liver cells .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. is incorrect as Bempedoic acid is an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels. Option: B. is incorrect as Ezetimibe acts by inhibiting intestinal absorption of dietary as well as biliary CH and phytosterols by interfering with a specific CH transporter protein NPC1L1 in the intestinal mucosa. Option: C. is incorrect as Lomitapide inhibits the microsomal triglyceride transfer protein (MTP or MTTP) which is necessary for very low-density lipoprotein (VLDL) assembly and secretion in the liver</p>\n<p><strong>Table:</strong></p><p>#MANTRA</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A G2P1 delivered a preterm baby at 36 weeks. The baby was admitted in the NICU for a week and was given expressed breast milk. Unfortunately, the baby did not survive. Which of the following drugs can be used to reduce the engorgement and pain of the lactating breasts?", "options": [{"label": "A", "text": "Cabergoline", "correct": true}, {"label": "B", "text": "Sumatriptan", "correct": false}, {"label": "C", "text": "Chlorpromazine", "correct": false}, {"label": "D", "text": "Pramipexole", "correct": false}], "correct_answer": "A. Cabergoline", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Cabergoline Cabergoline is the preferred drug for the treatment of hyperprolactinemia,  reduces breast engorgement or breast pain because of greater efficacy and lower adverse effects.</p>\n<p><strong>Highyeild:</strong></p><p>Dopamine Receptor Agonists Bromocriptine, cabergoline, and quinagolide effectively reduce PRL levels, thereby relieving the inhibitory effect of hyperprolactinemia on ovulation and permitting most patients with prolactinomas to become pregnant. Cabergoline Cabergoline is an ergot derivative with a longer t 1/2 (~65 h), higher affinity, and greater selectivity for the DA D2 receptor. Cabergoline should be stopped when pregnancy occurs, though no teratogenic effect has been observed. Cabergoline is also beneficial in acromegaly due to pituitary adenoma</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B. is incorrect as Sumatriptan is indicated in migraine therapy. Option: C. is incorrect as Chlorpromazine is First-Generation Antipsychotics with Low-potency D2 antagonist property, indicated for schizophrenia and acute mania. Option: D. is incorrect as Pramipexole is selective D2/D3 receptor agonists, indicated for monotherapy in early PD as well as to supplement levodopa-carbidopa in advanced cases.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following drugs for diabetes is LEAST likely to cause weight gain?", "options": [{"label": "A", "text": "Liraglutide", "correct": true}, {"label": "B", "text": "Pioglitazone", "correct": false}, {"label": "C", "text": "Repaglinide", "correct": false}, {"label": "D", "text": "Insulin glulisine", "correct": false}], "correct_answer": "A. Liraglutide", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Liraglutide GLP-1 receptor agonists are usually associated with weight loss due to their ability to enhance satiety. In clinical trials, liraglutide caused both improvement in glycemic control and weight loss.</p>\n<p><strong>Highyeild:</strong></p><p>GLP-1 Receptor Agonists GLP-1 is an important incretin released from the gut in response to ingested glucose. It induces insulin release from pancreatic Î² cells, inhibits glucagon release from Î± cells, slows gastric emptying and suppresses appetite by activating specific GLP-1 receptors, which are cell surface GPCR. Example of GLP 1 receptor agonist- Exenatide, Dulaglutide. Liraglutide- Longer-acting GLP-1 agonist Injected s.c. once daily , alone or added to oral metformin Â± SU or pioglitazone, it has achieved improved glycaemic control in type 2 diabetics. Nausea and diarrhoea are the frequent side effects, but decrease in incidence over time. Use of liraglutide is attended by weight loss and it is approved for use in obesity. Hypoglycaemia is rare with exenatide/liraglutide monotherapy, but can occur when combined with SUs/metformin. Acute pancreatitis is reported in a few patients taking GLP-1 agonists.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B- is incorrect as pioglitazone causes weight gain as an adverse effect. Option: C- is incorrect as Repaglinide causes weight gain as an adverse effect. Option: D- is incorrect as Insulin glulisine causes weight gain as an adverse effect.</p>\n<p><strong>Table:</strong></p><p>#MANTRA Oral hypoglycemic drugs DRUG CLASS MOA EFFECT ON PLASMA INSULIN RISK OF HYPOGLYCEMIA 1.     Sulfonylurea (Glimepiride) Stimulates insulin secretion â†‘ Yes 2. Biguanides (Metformin) Decreases hepatic production of glucose â†‘ No 3.               Thiazolidinediones (Pioglitazone) Activate the transcription factor peroxisome proliferator-activated receptor gamma (PPAR-Î³) â†“â†“ No 4. DPP4 inhibitor (Sitagliptin, Vildagliptin) Increases glucose dependent insulin release, decreases secretion of glucagon â†‘ No 5. SGLT2 Inhibitor (Dapagliflozin) Increases urinary glucose excretion â†” No</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following anti leprosy medications causes skin pigmentation?", "options": [{"label": "A", "text": "Ofloxacin", "correct": false}, {"label": "B", "text": "Dapsone", "correct": false}, {"label": "C", "text": "Clofazimine", "correct": true}, {"label": "D", "text": "Rifampicin", "correct": false}], "correct_answer": "C. Clofazimine", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Clofazimine Clofazimine is an anti leprosy drug. The major disadvantage is reddish-black discolouration of skin , especially on exposed parts. Discoloration of hair and body secretions may also occur, but is harmless. Dryness of skin, itching and scaling is often troublesome.</p>\n<p><strong>Highyeild:</strong></p><p>Clofazimine (Clo) It is a dye with leprostatic and antiinflammatory properties. The putative mechanisms of antileprotic action of clofazimine are: Interference with template function of DNA in M. Leprae Alteration of membrane structure and its transport function. Disruption of mitochondrial electron transport chain. It accumulates in macrophages and gets deposited as needle shaped crystals in many tissues including subcutaneous fat Clofazimine is used as a component of multidrug therapy (MDT) of leprosy. Because of its antiinflammatory property, it is valuable in lepra reaction Clofazimine is to be avoided during early pregnancy and in patients with liver or kidney damage.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A . Ofloxacin can cause skin/hypersensitivity: rash, pruritus, photosensitivity, urticaria, swelling of lips, etc Option: B . Dapsone can cause Cutaneous reactions including itching, allergic rashes, fixed drug eruption, hypermelanosis, phototoxicity and rarely exfoliative dermatitis. Option: D . Rifampicin causes orange red discolouration of body fluids.</p>\n<p><strong>Table:</strong></p><p>#MANTRA</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following diuretics is matched correctly with its location of action. Osmotic diuretics - Distal convoluted tubule. Thiazide diuretics - proximal convoluted tubule. Carbonic anhydrase inhibitors - proximal convoluted tubule. Potassium sparing diuretics - collecting duct Select the correct answer from the given below code:", "options": [{"label": "A", "text": "A,B,C", "correct": false}, {"label": "B", "text": "C,D", "correct": true}, {"label": "C", "text": "B,C,D", "correct": false}, {"label": "D", "text": "A,B", "correct": false}], "correct_answer": "B. C,D", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>C,D Site of action of Thiazides, CA inhibitors, and K sparing diuretics are correctly matched. Thiazide diuretics - proximal convoluted tubule. Carbonic anhydrase inhibitors - proximal convoluted tubule. Potassium sparing diuretics - collecting duct</p>\n<p><strong>Highyeild:</strong></p><p>Major locations of ion and water exchange in the nephron, showing sites of action of the diuretic drugs. Option with Osmotic diuretics - Distal convoluted tubules are incorrect as they are Pharmacologically inert substances â€” given in large quantities sufficient to raise osmolarity of plasma and tubular fluid. Target descending loop of Henle, PCT.</p>\n<p><strong>Table:</strong></p><p>#MANTRA DIURETIC MOA USES Carbonic Anhydrase Inhibitors (Acetazolamide) Inhibits carbonic anhydrase located intracellularly (cytoplasm) and on the apical membrane of the proximal tubular epithelium Glaucoma Epilepsy Altitude sickness Diuretic resistance Metabolic alkalosis Familial periodic paralysis Osmotic Diuretics (Mannitol) Pharmacologically inert substances â€” given in large quantities sufficient to raise osmolarity of plasma and tubular fluid. Elevated intraocular pressure Elevated intracranial pressure Dialysis disequilibrium syndrome Diagnosis of bronchial hyperreactivity Urologic irrigation Loop Diuretics; High-Ceiling Diuretics (Furosemide) Inhibitors of Na+-K+-2Clâ€“ Symport Acute pulmonary edema Edema associated with congestive heart failure, liver cirrhosis, chronic kidney disease, and nephrotic syndrome Hyponatremia Hypercalcemia Hypertension Thiazide Diuretics (Hydrochlorothiazide) Inhibitors of Na+-Clâ€“ Symport Hypertension Edema associated with congestive heart failure, liver cirrhosis, chronic kidney disease, and nephrotic syndrome Nephrogenic diabetes insipidus Kidney stones caused by Ca2+ crystals K+-Sparing Diuretics (Amiloride Triamterene) Inhibitors of Renal Epithelial Na+ Channels Hypertension Edema associated with congestive heart failure, liver cirrhosis, and chronic kidney disease Liddle syndrome Lithium-induced nephrogenic diabetes insipidus Aldosterone Antagonists; K+-Sparing Diuretics Mineralocorticoid Receptor Antagonists Hypertension Edema associated with congestive heart failure, liver cirrhosis, chronic kidney disease Primary hyperaldosteronism Acute myocardial infarction (eplerenone) Heart failure (in combination with standard therapy) Polycystic ovary disease</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A patient with a known case of diabetes, shows microalbuminuria on urine analysis, done twice at an interval of 6 months. Renal function tests are normal. Which of the following drugs is not useful in preventing the progression of renal damage?", "options": [{"label": "A", "text": "Finerenone", "correct": false}, {"label": "B", "text": "Hydrochlorothiazide", "correct": true}, {"label": "C", "text": "Angiotensin receptor blockers", "correct": false}, {"label": "D", "text": "SGLT2 inhibitor", "correct": false}], "correct_answer": "B. Hydrochlorothiazide", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Hydrochlorothiazide Hydrochlorothiazide is not useful in preventing the progression of renal damage. It is a thiazide diuretic, it causes hyperglycemia (increases blood sugar) and can worsen this patient condition.</p>\n<p><strong>Highyeild:</strong></p><p>Thiazide Diuretics- They are medium efficacy diuretics with primary site of action in the cortical diluting segment or the early DT (Site III). They inhibit Na+ â€“ClÂ¯ symport at the luminal membrane. Uses- Edema- Thiazides may be used for mild-to-moderate cases. Hypertension- Thiazides and related diuretics, especially chlorthalidone and indapamide are one of the first line drugs. Diabetes insipidus- Thiazides decrease positive free water clearance and are the only drugs effective in nephrogenic diabetes insipidus. Hypercalciuria with recurrent calcium stones in the kidney . Thiazides act by reducing Ca2+ excretion</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. is correct as Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. Option: C. ARBs are useful in preventing the progression of renal damage in diabetes patients. Option: D. SGLT2 inhibitors are useful in preventing the progression of renal damage in diabetes patients.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Coagulation profile monitoring is required for which of the following drugs?", "options": [{"label": "A", "text": "Lepirudin", "correct": true}, {"label": "B", "text": "Enoxaparin", "correct": false}, {"label": "C", "text": "Fondaparinux", "correct": false}, {"label": "D", "text": "Dabigatran", "correct": false}], "correct_answer": "A. Lepirudin", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Lepirudin Lepirudin is a recombinant form of hirudin, should be used cautiously in patients with decreased renal function, and serum creatinine and aPTT should be monitored daily.</p>\n<p><strong>Highyeild:</strong></p><p>Other Parenteral Anticoagulants Desirudin and Lepirudin- Desirudin and lepirudin are recombinant forms of hirudin. Desirudin is indicated for thromboprophylaxis in patients undergoing elective hip replacement surgery. Both desirudin and lepirudin are also used for treating thrombosis in the setting of heparin-induced thrombocytopenia . Desirudin and lepirudin are eliminated by the kidneys; the t 1/2 is about 2 h after subcutaneous administration and about 10 min after intravenous infusion. Both drugs should be used cautiously in patients with decreased renal function, and serum creatinine and aPTT should be monitored daily.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B. Enoxaparin is a LMWH and patients with renal impairment may require monitoring with an antiâ€“factor Xa assay because this condition can prolong the t 1/2 and slow the elimination of LMWH Option: C. Fondaparinux does not require laboratory monitoring of aPTT, and is a longer acting alternative to LMW heparins. Option: D. Dabigatran is an oral direct thrombin inhibitor and does not require laboratory monitoring of aPTT.</p>\n<p><strong>Table:</strong></p><p>#MANTRA</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which hypoglycemic drug increases the risk of urinary tract infections (UTI)?", "options": [{"label": "A", "text": "Metformin", "correct": false}, {"label": "B", "text": "Teneligliptin", "correct": false}, {"label": "C", "text": "Dapagliflozin", "correct": true}, {"label": "D", "text": "Pioglitazone", "correct": false}], "correct_answer": "C. Dapagliflozin", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Dapagliflozin Dapagliflozin is an SGLT2 inhibitor and causes glycosuria which can predispose to urinary and genital infections, electrolyte imbalance, ketoacidosis and increased urinary frequency.</p>\n<p><strong>Highyeild:</strong></p><p>SGLT2 inhibitors reduce the rate of glucose reclamation in the proximal tubule and shift the renal threshold for glucose excretion from about 180 to 50 mg/dL. After once daily dosing, they produce round-the-clock glucosuria and lower blood glucose levels. Used alone or in combination with other antidiabetic drugs, they r educe HbA1C levels by 0.5â€“1.0%, but do not cause hypoglycemia. They are contraindicated in patients with renal insufficiency. The most common adverse effects with SGLT2 inhibitors are female genital mycotic infections (for example, vulvovaginal candidiasis), urinary tract infections, and urinary frequency</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. Metformin causes diarrhea, nausea, lactic acidosis as adverse effects. Option: B. Teneligliptin causes URTI, nasopharyngitis as adverse effects. Option: D. Pioglitazone causes peripheral edema, CHF, weight gain, fractures, macular edema as adverse effects.</p>\n<p><strong>Table:</strong></p><p>#MANTRA DRUG CLASS MOA EFFECT ON PLASMA INSULIN RISK OF HYPOGLYCEMIA Sulfonylurea (Glimepiride) Stimulates insulin secretion â†‘ Yes Biguanides (Metformin) Decreases hepatic production of glucose â†‘ No Thiazolidinediones (Pioglitazone) Activate the transcription factor peroxisome proliferator-activated receptor gamma (PPAR-Y) â†“â†“ No DPP4 inhibitor (Sitagliptin, Vildagliptin) Increases glucose dependent insulin release, decreases secretion of glucagon â†‘ No SGLT2 Inhibitor (Dapagliflozin) Increases urinary glucose excretion â†” No</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Patient with pulmonary aspergillosis was treated with Voriconazole. Which of the following is false about Voriconazole?", "options": [{"label": "A", "text": "Should be taken on empty stomach", "correct": false}, {"label": "B", "text": "Needs therapeutic drug monitoring", "correct": false}, {"label": "C", "text": "Should be co-administered with pyrazinamide", "correct": true}, {"label": "D", "text": "Needs loading dose", "correct": false}], "correct_answer": "C. Should be co-administered with pyrazinamide", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Should be co-administered with pyrazinamide Voriconazole is hepatotoxic and pyrazinamide is also highly hepatotoxic Anti TB drug, when co administered together can precipitate hepatic damage. Hence these should not be co-administered.</p>\n<p><strong>Highyeild:</strong></p><p>Voriconazole It is a second generation broad-spectrum triazole introduced for difficult to treat fungal infections. Voriconazole is the drug of choice for invasive aspergillosis, disseminated infections caused by fluconazole resistant Candida, Fusarium infections, and febrile neutropenia not responding to antibacterial therapy. It is also active against histoplasmosis and blastomycosis. Serious cases are first treated i.v. followed by oral voriconazole. Voriconazole is also an inhibitor of CYP isoenzymes Rashes, photosensitivity, rise in liver enzymes and QTc prolongation can occur. Short lasting visual disturbances are common after i.v. injection, and an acute reaction is also possible</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. is correct as it should be taken empty stomach as It is completely absorbed orally, except when taken with a fatty meal. Option: B. is correct as Therapeutic drug monitoring is frequently used, with target serum concentrations between 1 and 5 mg/L thought to maximize efficacy and minimize adverse events. Option: D. is correct as Treatment is usually initiated with an intravenous infusion of 6 mg/kg every 12 h for two doses, followed by 3â€“4 mg/kg every 12 h, administered no faster than 3 mg/kg/h.</p>\n<p><strong>Table:</strong></p><p>#MANTRA DEEP MYCOSES DRUGS Invasive aspergillosis Immunosuppressed Non immunosuppressed Blastomycosis Rapidly progressive or CNS Indolent and non-CNS Candidiasis Deeply invasive Coccidioidomycosis Rapidly progressing Indolent Meningeal Voriconazole, isavuconazole, amphotericin B Voriconazole, isavuconazole, amphotericin B, itraconazole amphotericin B, Itraconazole Amphotericin B, fluconazole voriconazole, caspofungin, micafungin, anidulafungin Amphotericin B Itraconazole, fluconazole Fluconazole, intrathecal amphotericin B</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A patient presents with complaints of a cough producing tenacious white sputum. Which of the following statements is true about the drug that could be prescribed for this condition?", "options": [{"label": "A", "text": "Codeine as it is a potent drug and quickly relieves symptoms.", "correct": false}, {"label": "B", "text": "Bromhexine and Dextromethorphan syrup as they liquefy sputum as reduce cough due to antitussive effect", "correct": false}, {"label": "C", "text": "Dextromethorphan alone as it does not have addictive potential like codeine", "correct": false}, {"label": "D", "text": "Bromhexine as it liquefies sputum", "correct": true}], "correct_answer": "D. Bromhexine as it liquefies sputum", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Bromhexine as it liquefies sputum Here patient is having sputum which means it is a productive cough, and we need to remove sputum to avoid further infection. So DOC will be expectorant. Drugs for Productive cough- B-Bromhexine A-Ambroxol N- N Acetylcysteine So option D is correct.</p>\n<p><strong>Highyeild:</strong></p><p>Mucolytics Bromhexine - is a mucolytic and mucokinetic , capable of inducing thin copious bronchial secretion. It depolymerises mucopolysaccharides directly as well as by liberating lysosomal enzymesâ€”network of fibres in tenacious sputum is broken. It is particularly useful if mucus plugs are present. Side effects are rhinorrhoea and lacrimation, nausea, gastric irritation, hypersensitivity. Mucolytics are specifically useful in patients with tracheostomy, asthmatic bronchitis, cystic fibrosis, etc. who have thick tenacious sputum or mucus plugs.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: A. is incorrect as codeine is antitussive which is not useful in productive cough. Option: B. is incorrect as Dextromethorphan is an antitussive agent having no mucolytic action. Option: C. is incorrect as Dextromethorphan is an antitussive agent having no mucolytic action.</p>\n<p><strong>Table:</strong></p><p>#MANTRA</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Inhaled Nitric oxide (iNO) is used for________:", "options": [{"label": "A", "text": "Persistent pulmonary hypertension of newborn", "correct": true}, {"label": "B", "text": "Unstable angina", "correct": false}, {"label": "C", "text": "Obstructive Sleep apnea", "correct": false}, {"label": "D", "text": "Erectile dysfunction", "correct": false}], "correct_answer": "A. Persistent pulmonary hypertension of newborn", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Persistent pulmonary hypertension of newborn Inhaled NO is FDA-approved for only one indication, persistent pulmonary hypertension of the newborn.</p>\n<p><strong>Highyeild:</strong></p><p>Nitric Oxide - Nitric oxide is a free-radical gas now known as a critical endogenous cell-signaling molecule with an increasing number of potential therapeutic applications. Diagnostic Uses- Inhaled NO can be used during cardiac catheterization to evaluate the pulmonary vasodilating capacity of patients with heart failure and infants with congenital heart disease. Inhaled NO also is used to determine the diffusion capacity (DL ) across the alveolar-capillary unit. Therapeutic Uses - Inhaled NO selectively dilates the pulmonary vasculature and has potential as a therapy for numerous diseases associated with increased pulmonary vascular resistance. Inhaled NO is FDA-approved for only one indication, persistent pulmonary hypertension of the newborn.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B. is incorrect as Inhaled NO is FDA-approved for only one indication, persistent pulmonary hypertension of the newborn. Option: C. is incorrect as Inhaled NO is FDA-approved for only one indication, persistent pulmonary hypertension of the newborn. Option: D. is incorrect as Inhaled NO is FDA-approved for only one indication, persistent pulmonary hypertension of the newborn.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 45-year-old patient presented with enterococcal endocarditis, who is allergic to penicillin. Which of the following drugs should be preferred in this patient?", "options": [{"label": "A", "text": "Vancomycin", "correct": true}, {"label": "B", "text": "Ceftriaxone", "correct": false}, {"label": "C", "text": "Piperacillin", "correct": false}, {"label": "D", "text": "Aztreonam", "correct": false}], "correct_answer": "A. Vancomycin", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Vancomycin Vancomycin- In combination with an aminoglycoside, it may be used for enterococcal endocarditis in patients with serious penicillin allergy or for penicillin-resistant isolates.</p>\n<p><strong>Highyeild:</strong></p><p>Vancomycin- It is a glycopeptide antibiotic. Vancomycin acts by inhibiting bacterial cell wall synthesis. Vancomycin is not absorbed orally . After i.v. administration, it is widely distributed, penetrates serous cavities, inflamed meninges. Systemic toxicity of vancomycin is relatively high. It can cause concentration-dependent nerve deafness which may be permanent. Given orally (125â€“500 mg 6 hourly), it is the second choice drug to metronidazole for antibiotic associated pseudomembranous enterocolitis caused by C. difficile.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options: - Option: B. Ceftriaxone shows high efficacy in a wide range of serious infections including bacterial meningitis (especially in children), multi resistant typhoid fever, complicated urinary tract but not for enterococcal endocarditis. Option: C. Piperacillin is employed for treating serious gram-negative infections in neutropenic/immunocompromised or burn patients but not for enterococcal endocarditis. Option: D. is incorrect as main indications of aztreonam are hospital-acquired infections originating from urinary, biliary, gastrointestinal and female genital tracts but not for enterococcal endocarditis.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}];
            if (!Array.isArray(questions) || questions.length === 0) {
                throw new Error("Questions data is empty or invalid");
            }
            debugLog(`Successfully parsed ${questions.length} questions`);
        } catch (e) {
            console.error("Failed to parse questions_json:", e);
            document.getElementById(